Search results: (10000)
News Is there a link between Parvovirus B19 infection and autoimmune thyroid diseases?
Autoimmune thyroid diseases are among the most common autoimmune disorders, with a worldwide prevalence of around 10%. The study presented below, recently published in the International Journal of Endocrinology and Metabolism, examined the connection between Parvovirus B19 infection (the cause of erythema infectiosum in children) and these diseases.
News INFOGRAPHIC: Determining the Target Intraocular Pressure in Glaucoma Therapy
The goal of glaucoma treatment is to preserve the visual field and the quality of life of patients. Currently, the only approach to preserving the visual field of patients is to reduce intraocular pressure (IOP). Its target value should be determined for each patient with consideration of individual risk factors. The following comprehensive infographic shows which factors should be considered according to the current recommendations of the European Glaucoma Society (EGS).
News Efficacy and Safety of Two Pharmacokinetically-Driven Prophylactic Regimens in People with Hemophilia A
Standard prophylaxis for bleeding in hemophilia A, based on the administration of coagulation factor VIII (FVIII), depends on the patient's weight, the severity of the coagulation factor deficiency, and the nature of bleeding episodes. The current trend, however, is an individualized approach in prophylaxis, which can improve clinical outcomes and optimize bleeding disorder therapy. A clinical study evaluated the efficacy and safety of two prophylactic regimens with different target trough levels of FVIII.
News Pharmacokinetics and Safety of Bilastine 10 mg in Children Aged 6–11 Years
The second-generation antihistamine bilastine is approved in Europe for the treatment of allergic rhinoconjunctivitis and urticaria from the age of 6 years. Recently, results from two post hoc analyses on the pharmacokinetics and safety of bilastine in children aged 6–11 years have been published.
News Administration of Erdosteine After Severe Course of COVID-19 in the Early Period After Patient Discharge From Medical Facility
Erdosteine is a mucomodulatory drug used in the therapy of various acute and chronic respiratory diseases. Its mechanism of action is considered complex based on available evidence, encompassing antioxidant and antibacterial effects along with its mucolytic effect. Two clinical studies assessed changes in respiratory distress parameters and quality of life in patients taking this medication in the early period after discharge from medical facilities where they were hospitalized for severe COVID-19 (respiratory failure, pneumonia).
News Maintenance of Remission with Tofacitinib in Patients with UC – Results of the OCTAVE Open Study
Tofacitinib is indicated for the treatment of ulcerative colitis (UC) in cases where conventional treatment or monoclonal antibodies do not yield sufficient results. Key benefits of this medication include oral administration and predictable kinetics. The long-term efficacy of tofacitinib was studied in the OCTAVE Open study.
News Update of International Recommendations for the Diagnosis and Treatment of Hereditary Angioedema from 2021
The aim of the 2021 update of the recommendations for the diagnosis and treatment of hereditary angioedema (HAE) is to help doctors answer important clinical questions: How to diagnose HAE? When and what prophylactic treatment to administer? What are the treatment goals? How do treatment of children and pregnant women differ? How to monitor disease activity, its impact, and control?
News How Does Emicizumab Work in Obese Adults with Hemophilia A?
What is the annual bleeding rate and minimum concentration of emicizumab in obese adults with hemophilia A compared to non-obese individuals? Answers were sought by the authors of a pooled post hoc analysis of the HAVEN 1, 3, and 4 studies, the results of which were presented in the poster section of the 2021 ISTH virtual congress. Based on modeling, body weight appears to be an important predictor of emicizumab pharmacokinetics.
News Effects of Telmisartan on Vascular Endothelial Functions, Inflammation Parameters, and Insulin Resistance in Patients with CHD and DM
Patients with coronary heart disease (CHD) and diabetes mellitus (DM) often have dysfunctional vascular endothelium, increased inflammatory markers, and insulin resistance. The study presented below investigated the effects of telmisartan on these parameters associated with disease progression and worse prognosis.
News Effect of Romiplostim in Refractory ITP with Possibility of Maintaining Response Without Treatment – Case Report
This case report from the United States features an ideal therapeutic response to romiplostim in a patient with refractory immune thrombocytopenia (ITP). After several years of successful therapy, the medication could even be gradually discontinued while maintaining the therapeutic response.
News Impact of Dabigatran and Warfarin Treatment on the Risk of Acute Kidney Injury in Patients with Atrial Fibrillation
What clinical characteristics in patients with non-valvular atrial fibrillation may indicate a higher risk of acute kidney injury? Does the modality of anticoagulation therapy play a role in its incidence? These questions were the focus of an extensive retrospective study conducted in an Asian setting.
News When to Stop Dabigatran Anticoagulation Treatment Before Catheter Ablation in Patients with Atrial Fibrillation?
Catheter ablation is now a standard method of treating atrial fibrillation. Its most common complications are bleeding and thromboembolism. The aim of the analysis of 2 clinical studies presented below, whose conclusions were recently published, was to determine the optimal timing of stopping dabigatran anticoagulation treatment before this procedure.
News ADCT – a simple tool for self-diagnosis of patients with severe atopic dermatitis
Atopic dermatitis (AD) is a chronic inflammatory disease not only of childhood. It can negatively affect the quality of life despite being treatable. Control and management of the disease in different areas of life can be easily evaluated using the ADCT questionnaire.
News Fixed Combination of Trastuzumab and Pertuzumab for Subcutaneous Administration in Patients with Early Breast Cancer
At a symposium focused on breast cancer, held in December 2019 in San Antonio, Texas, preliminary results of the FeDeriCa clinical study were presented – comparing the pharmacokinetics, efficacy, and safety of a fixed combination of trastuzumab and pertuzumab for subcutaneous administration versus intravenous administration in patients with early-stage HER2-positive breast cancer. Based on the presented results, the drug received approval from the U.S. Food and Drug Administration (FDA).
News Results of Prophylactic Treatment of Severe von Willebrand Disease with Recombinant vWF
The phase III study cited below evaluated the efficacy and safety of 12-month prophylaxis with recombinant von Willebrand factor (rvWF) in 23 patients with severe von Willebrand disease (vWD), who had previously been treated either on-demand (during spontaneous bleeding episodes) or had been on prophylaxis with plasma-derived vWF (pdvWF).
News Influence of ARNI on the Efficacy and Safety of Empagliflozin in the Treatment of Heart Failure with Reduced Ejection Fraction
Pharmacological inhibition of neprilysin and the AT1 receptor for angiotensin II (ARNI) through sacubitril/valsartan reduces cardiovascular (CV) mortality and the risk of hospitalization for heart failure. The same benefit has also been demonstrated with the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i), also known as gliflozins. A pre-specified sub-analysis of the EMPEROR-Reduced study evaluated whether the benefit of SGLT2i is also significant in patients treated with ARNI.
News Post-COVID-19 Patient Care from the Perspective of Experts Across Fields
For many patients with COVID-19, overcoming the acute phase is crucial, but we now know that the disease may not end there. Some patients even manage the acute stage with very mild symptoms, and significant difficulties arise later in the form of 'post-COVID syndrome.' This issue was discussed in detail at a January webinar by leading experts from various fields.
News Summary Analysis of HAVEN 1–4 and Patient Case Studies from ÚHKT
MUDr. Věra Geierová from the Institute of Hematology and Blood Transfusion in Prague prepared a summary of what was discussed about emicizumab during the ASH 2020 congress for this year's Prague Hematology Days. In this context, she highlighted the comprehensive analysis of phase 3 HAVEN 1–4 studies, which assessed the safety and efficacy of emicizumab in individuals with hemophilia A with or without FVIII inhibitors.
News Benefits of Physical Activity for Individuals with Hemophilia – Recommendations of the MEMO Group
Regular physical activity can increase joint stability and function in individuals with hemophilia, reduce the risk of injury, improve quality of life, and have other positive effects. However, according to recent findings, a regular exercise program is not sufficiently emphasized in comprehensive hemophilia therapy. Therefore, a group of Italian experts has created a consensus summarizing current knowledge about the benefits of exercise for individuals with hemophilia and recommendations for physical activity.
News Do ACE Inhibitors Have a Protective Effect in People with COVID-19?
Although the COVID-19 pandemic has not lasted even a year, a number of studies have already been processed, examining the influence of various factors on the morbidity and mortality of patients. The presented meta-analysis investigated the influence of ACE inhibitors on the mortality of patients with this disease.
News Should patients with primary immunodeficiencies fear COVID-19 more than the general population?
The body fights the new SARS-CoV-2 virus, which causes COVID-19, in a similar way to other viral infections - by intensely engaging the immune system. But what if it's weakened?
News Prediabetes as a Risk Factor for Overall Mortality and Development of CVD
Prediabetes represents a glucose metabolism disorder with a high risk of developing diabetes. According to the expert panel of the American Diabetes Association (ADA), this risk is up to 70%. A recently published meta-analysis confirms that prediabetes is a significant risk factor for mortality and the development of cardiovascular (CV) diseases not only in the general population but also in patients with known CV disease, and its treatment should therefore be part of cardiovascular prevention.
News Overview of the Efficacy of the Fixed Combination Aclidinium-Bromide/Formoterol-Fumarate in the Maintenance Treatment of COPD
Fixed combination inhalation medications have become the cornerstone of pharmacotherapy for moderate to severe chronic obstructive pulmonary disease (COPD). American authors have published an overview of study results evaluating the efficacy and safety of one of the newest fixed combinations of LABA/LAMA, aclidinium-bromide and formoterol-fumarate (AB/FF), in the maintenance treatment of COPD compared to placebo or other medications. These clinical studies investigated the extent to which regular use of this fixed combination alleviates COPD symptoms, improves lung function, reduces the incidence of exacerbations, and increases exercise tolerance.